<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492401</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00246</org_study_id>
    <secondary_id>OSU 07017</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <nct_id>NCT00492401</nct_id>
  </id_info>
  <brief_title>Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of Decitabine in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well decitabine works in treating patients with
      previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine,
      work in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the rate of complete remission (CR) in patients with previously untreated acute
      myeloid leukemia treated with decitabine.

      SECONDARY OBJECTIVES:

      I. Determine the rate of overall survival at 1 year in patients treated with this drug.

      II. Determine the overall response rate (CR, incomplete CR, and partial remission) in
      patients treated with this drug.

      III. Correlate the biological activity of decitabine with clinical endpoints and maximum
      concentration of plasma decitabine.

      IV. Correlate intracellular concentration of decitabine with global DNA methylation, other
      biological endpoints, and clinical response.

      OUTLINE:

      Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in
      the absence of disease progression or unacceptable toxicity.

      Patients undergo bone marrow aspiration and blood sample collection periodically for
      pharmacological and correlative studies. Samples are analyzed for gene expression,
      methylation of gene promoters, fetal hemoglobin (HgF), DNMT1 protein expression, maximum
      concentration of plasma decitabine, and global DNA methylation. Samples are analyzed by
      RT-PCR, Bio-COBRA, matrix-assisted laser desorption ionization time-of-flight mass
      spectrometry, SDS-PAGE (polyacrylamide gel electrophoresis), immunoblotting, and LC-MS/MS.

      After completion of study treatment, patients are followed for at least 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Remission</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Per International Working Group criteria: Morphologic complete remission (CRm): Defined as morphologic leukemia-free state, including &lt;5% blasts in BM aspirate with marrow spicules and a count of &gt; 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC &gt; 1000/uL, platelet count &gt; 100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. Morphologic complete remission with incomplete blood count recovery (CRi): Defined as CR with the exception of neutropenia &lt;1000/uL or thrombocytopenia &lt;100,000/ul. Complete Remission Rate (CRm + CRi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of DNA Methylation in Peripheral Blood or Bone Marrow Cells</measure>
    <time_frame>From baseline to up to day 28 of course 1</time_frame>
    <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells</measure>
    <time_frame>Pre treatment</time_frame>
    <description>Expression studies were conducted using quantitative RT PCR. Expression of DNMT were normalized to the internal control to the ABL and levels of miR-29 to RNA U44.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HbF in Peripheral Blood or Marrow Cells</measure>
    <time_frame>From baseline to up to days 28 of course 2</time_frame>
    <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Gene Expression in Peripheral Blood or Bone Marrow</measure>
    <time_frame>From baseline to up to day 28 of course 1</time_frame>
    <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>5-aza-dCyd</other_name>
    <other_name>5AZA</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>HPLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>gene expression profiling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matrix-assisted laser desorption/ionization time of flight mass spectrometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>MALDI-TOF Mass Spectrometry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed acute myeloid leukemia (AML) meeting 1 of
             the following criteria:

               -  At least 60 years of age and not a candidate for or refused standard induction
                  treatment

               -  Poor risk cytogenetics

               -  AML following antecedent hematologic disorder

               -  Therapy-related AML

               -  Secondary AML

          -  No granulocytic sarcoma as sole site of disease

          -  No active CNS disease or CNS relapse

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Total bilirubin &lt; 2.0 mg/dL

          -  Creatinine &lt; 2.0 mg/dL

          -  AST and ALT &lt; 2.5 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No NYHA class III or IV congestive heart failure

          -  No uncontrolled infection

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to decitabine that are not easily managed

          -  No other uncontrolled illness including, but not limited to, any of the following:

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Serious cardiac arrhythmia

               -  Psychiatric illness or social situations that would preclude compliance with
                  study requirements

          -  No active second malignancy involving the blood or marrow or likely to progress and
             require therapy in the next 6 months

          -  No prior therapy for AML except emergency leukapheresis or hydroxyurea for
             leukocytosis

          -  No prior azacitidine or decitabine

          -  No prior cytarabine or other conventional chemotherapy agents for antecedent
             hematologic disorders

               -  Prior myeloid growth factors, recombinant erythropoietin, thalidomide, or
                  lenalidomide allowed

          -  No concurrent palliative radiotherapy

          -  No other concurrent investigational agents

          -  No other concurrent direct anti-leukemia therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Blum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>October 22, 2015</results_first_submitted>
  <results_first_submitted_qc>May 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Decitabine</title>
          <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decitabine</title>
          <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complete Remission</title>
        <description>Per International Working Group criteria: Morphologic complete remission (CRm): Defined as morphologic leukemia-free state, including &lt;5% blasts in BM aspirate with marrow spicules and a count of &gt; 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC &gt; 1000/uL, platelet count &gt; 100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. Morphologic complete remission with incomplete blood count recovery (CRi): Defined as CR with the exception of neutropenia &lt;1000/uL or thrombocytopenia &lt;100,000/ul. Complete Remission Rate (CRm + CRi)</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Decitabine</title>
            <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Remission</title>
          <description>Per International Working Group criteria: Morphologic complete remission (CRm): Defined as morphologic leukemia-free state, including &lt;5% blasts in BM aspirate with marrow spicules and a count of &gt; 200 nucleated cells and no blasts with Auer rods, no persistent extramedullary disease, ANC &gt; 1000/uL, platelet count &gt; 100,000/uL. Patient must be independent of transfusions for a minimum of 1 week before each marrow assessment. Morphologic complete remission with incomplete blood count recovery (CRi): Defined as CR with the exception of neutropenia &lt;1000/uL or thrombocytopenia &lt;100,000/ul. Complete Remission Rate (CRm + CRi)</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of DNA Methylation in Peripheral Blood or Bone Marrow Cells</title>
        <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
        <time_frame>From baseline to up to day 28 of course 1</time_frame>
        <population>Data was not collected and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine</title>
            <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of DNA Methylation in Peripheral Blood or Bone Marrow Cells</title>
          <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
          <population>Data was not collected and analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells</title>
        <description>Expression studies were conducted using quantitative RT PCR. Expression of DNMT were normalized to the internal control to the ABL and levels of miR-29 to RNA U44.</description>
        <time_frame>Pre treatment</time_frame>
        <population>Only pre treatment samples available for testing for 23 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Responders</title>
            <description>Any patient that achieved a CR (Complete Response), or Incomplete CR was categorized as a responder.</description>
          </group>
          <group group_id="O2">
            <title>Non Responder</title>
            <description>Any patient that did not achieve a CR (Complete Response), or Incomplete CR was categorized as a non responder.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of DNMT Protein in Peripheral Blood or Bone Marrow Cells</title>
          <description>Expression studies were conducted using quantitative RT PCR. Expression of DNMT were normalized to the internal control to the ABL and levels of miR-29 to RNA U44.</description>
          <population>Only pre treatment samples available for testing for 23 patients</population>
          <units>delta delta CT values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Expression levels of MiR-29b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0056394" lower_limit="0.0037495" upper_limit="0.0075544"/>
                    <measurement group_id="O2" value="0.0024305" lower_limit="0.0014533" upper_limit="0.0042197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Expression levels of DNMT3a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000196066" lower_limit="0.000145407" upper_limit="0.000280477"/>
                    <measurement group_id="O2" value="0.000341819" lower_limit="0.000289839" upper_limit="0.000361753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Expression levels of miR-29b in pre treatment marrow samples from responding or non responding patients were compared using Wilcoxon rank sum tests</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Expression levels of DNMT3a in pre treatment marrow samples from responding or non responding patients were compared using Wilcoxon rank sum tests</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HbF in Peripheral Blood or Marrow Cells</title>
        <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
        <time_frame>From baseline to up to days 28 of course 2</time_frame>
        <population>Data was not collected and analyzed for this trial</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine</title>
            <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HbF in Peripheral Blood or Marrow Cells</title>
          <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
          <population>Data was not collected and analyzed for this trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Gene Expression in Peripheral Blood or Bone Marrow</title>
        <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
        <time_frame>From baseline to up to day 28 of course 1</time_frame>
        <population>Data was not collected and analyzed for this trial</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine</title>
            <description>Decitabine 20mg/m2/day IV over 1 hour, days 1-10, repeat cycle every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Gene Expression in Peripheral Blood or Bone Marrow</title>
          <description>Standard paired statistical tests, parametric and nonparametric, will be used to baseline with treatment values. With data collected serially over time, repeated measures analysis of variance will be used to analyze data.</description>
          <population>Data was not collected and analyzed for this trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy)</title>
          <description>Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
decitabine: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies
high performance liquid chromatography: Correlative studies
microarray analysis: Correlative studies
RNA analysis: Correlative studies
mass spectrometry: Correlative studies
DNA methylation analysis: Correlative studies
matrix-assisted laser desorption/ionization time of flight mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased left ventricular ejection fraction</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/gingivitis</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abnormal gait</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Documented infection</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hemorrhage/hematoma</sub_title>
                <description>Grade ≥ 3 in cycles 1 and 2</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After completing the target accrual of 33 subjects, the study was expanded to include 22 additional patients. All patients who received decitabine are included in the analyses, except for two who had not completed therapy at the time of the analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Blum, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-9273</phone>
      <email>William.Blum@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

